MX2022016532A - Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos. - Google Patents

Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.

Info

Publication number
MX2022016532A
MX2022016532A MX2022016532A MX2022016532A MX2022016532A MX 2022016532 A MX2022016532 A MX 2022016532A MX 2022016532 A MX2022016532 A MX 2022016532A MX 2022016532 A MX2022016532 A MX 2022016532A MX 2022016532 A MX2022016532 A MX 2022016532A
Authority
MX
Mexico
Prior art keywords
polypeptides
modified
agonize
polypeptide
bind
Prior art date
Application number
MX2022016532A
Other languages
English (en)
Inventor
Katelyn M Willis
Bryan Becklund
Brendan P Eckelman
John C Timmer
Florian Sulzmaier
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of MX2022016532A publication Critical patent/MX2022016532A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

En el presente se proporcionan polipéptidos que comprenden una IL-2 modificada, en los que la IL-2 modificada tiene una afinidad reducida por el receptor de IL-2 en relación con la IL-2 de tipo natural; en algunas modalidades, se proporcionan polipéptidos que comprenden una IL-2 modificada que se une y agoniza las células T activadas; también se proporcionan usos de los polipéptidos que comprenden una IL-2 modificada.
MX2022016532A 2020-07-02 2021-07-01 Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos. MX2022016532A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047681P 2020-07-02 2020-07-02
PCT/US2021/040061 WO2022006380A2 (en) 2020-07-02 2021-07-01 Polypeptides comprising modified il-2 polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016532A true MX2022016532A (es) 2023-04-12

Family

ID=77127075

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016532A MX2022016532A (es) 2020-07-02 2021-07-01 Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.

Country Status (12)

Country Link
US (1) US20230235005A1 (es)
EP (1) EP4175979A2 (es)
JP (1) JP2023532904A (es)
KR (1) KR20230035076A (es)
CN (1) CN116615440A (es)
AR (1) AR122863A1 (es)
AU (1) AU2021299552A1 (es)
CA (1) CA3184618A1 (es)
IL (1) IL299542A (es)
MX (1) MX2022016532A (es)
TW (1) TW202216745A (es)
WO (1) WO2022006380A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
GB2623654A (en) 2021-05-19 2024-04-24 Asher Biotherapeutics Inc Il-21 polypeptides and targeted constructs
WO2023133393A1 (en) * 2022-01-05 2023-07-13 Inhibrx, Inc. Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof
AU2023217152A1 (en) * 2022-02-11 2024-08-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Immunoconjugate and use thereof
WO2023212056A2 (en) * 2022-04-27 2023-11-02 Asher Biotherapeutics, Inc. Combination of cytokine fusion proteins with cd8 antigen binding molecules
WO2024008126A1 (en) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Il2 muteins and uses thereof
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
WO2024165500A1 (en) * 2023-02-06 2024-08-15 Merck Patent Gmbh Vhh-based nkp46 binders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE033349T2 (en) 2003-10-22 2017-11-28 Keck Graduate Inst Procedures for the Synthesis of Heteromultimer Polypeptides in Yeast Using an Hagloid Mating Strategy
WO2005091956A2 (en) * 2004-03-05 2005-10-06 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
CN106659757B (zh) * 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
EP3558339B1 (en) * 2016-12-22 2024-01-24 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US20210269497A1 (en) * 2018-06-22 2021-09-02 Cugene Inc Interleukin-2 variants and methods of uses thereof
BR112021012294A2 (pt) * 2019-01-07 2021-09-08 Inhibrx, Inc. Polipeptídeos compreendendo polipeptídeos de il-2 modificada e usos dos mesmos

Also Published As

Publication number Publication date
CA3184618A1 (en) 2022-01-06
JP2023532904A (ja) 2023-08-01
AR122863A1 (es) 2022-10-12
US20230235005A1 (en) 2023-07-27
TW202216745A (zh) 2022-05-01
WO2022006380A3 (en) 2022-02-24
EP4175979A2 (en) 2023-05-10
WO2022006380A2 (en) 2022-01-06
CN116615440A (zh) 2023-08-18
AU2021299552A1 (en) 2023-02-02
IL299542A (en) 2023-02-01
KR20230035076A (ko) 2023-03-10

Similar Documents

Publication Publication Date Title
MX2021008147A (es) Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos.
MX2022016532A (es) Polipeptidos que comprenden polipeptidos de il-2 modificados y usos de los mismos.
WO2020247843A3 (en) Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
EP4345453A3 (en) High throughput epitope identification and t cell receptor specificity determination using loadable detection molecules
WO2020142659A3 (en) Multi-specific protein molecules and uses thereof
MX2020002596A (es) Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.
TR201905437T4 (tr) İki işlevli polipeptidler.
MY197854A (en) Antibodies against signal-regulatory protein alpha and methods of use
MX2022012189A (es) Composiciones que comprenden una variante del polipéptido cas12i2 y usos de las mismas.
MX2019010445A (es) Metodos y composiciones para transducir y expandir linfocitos y regular la actividad de los mismos.
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
MX347197B (es) Epitopes de celulas t reguladoras, composiciones y usos para los mismos.
MX2022003367A (es) Polipeptidos moduladores de linfocitos t y metodos de uso de estos.
MX2021014476A (es) Polipeptidos multimericos moduladores de linfocitos t y metodos de uso de estos.
WO2020160156A3 (en) Anti-gal3 antibodies and uses thereof
NZ602634A (en) Vista regulatory t cell mediator protein, vista binding agents and use thereof
CY1110734T1 (el) Μεθοδος παραγωγης μονιμων ανθρωπινων κυτταρικων σειρων
MX2019009346A (es) Variantes de polipeptidos y usos de los mismos.
CR20220512A (es) Inmunoconjugados
BR112012011598A2 (pt) polipeptídeos de haemophilus parasuis e métodos de uso
MX2022013840A (es) Polipéptidos de unión a pd-1 canina y usos de los mismos.
MX2022012062A (es) Receptores de linfocitos t.
WO2023280307A9 (en) Mutant il-15 compositions and methods thereof
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.
MX2024002203A (es) Composicion farmaceutica que contiene proteina de fusion.